These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 36386462)

  • 21. Efficacy and safety of nintedanib and docetaxel in patients with previously treated lung non-squamous non-small cell lung cancer: a multicenter retrospective real-world analysis.
    Ljubicic L; Janzic U; Unk M; Terglav AS; Mohorcic K; Seiwerth F; Bitar L; Badovinac S; Plestina S; Korsic M; Kukulj S; Samarzija M; Jakopovic M
    Radiol Oncol; 2023 Sep; 57(3):397-404. PubMed ID: 37665737
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of treatment timing and sequence of immune checkpoint inhibitors and anti-angiogenic agents for advanced non-small cell lung cancer: A systematic review and meta-analysis.
    Matsumoto K; Shiroyama T; Kuge T; Miyake K; Yamamoto Y; Yoneda M; Yamamoto M; Naito Y; Suga Y; Fukushima K; Koyama S; Iwahori K; Hirata H; Nagatomo I; Takeda Y; Kumanogoh A
    Lung Cancer; 2021 Dec; 162():175-184. PubMed ID: 34823108
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of immune checkpoint inhibitor monotherapy in pretreated elderly patients with non-small cell lung cancer.
    Yamaguchi O; Imai H; Minemura H; Suzuki K; Wasamoto S; Umeda Y; Osaki T; Kasahara N; Uchino J; Sugiyama T; Ishihara S; Ishii H; Naruse I; Mori K; Kotake M; Kanazawa K; Minato K; Kagamu H; Kaira K
    Cancer Chemother Pharmacol; 2020 Apr; 85(4):761-771. PubMed ID: 32193618
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Front-Line ICI-Based Combination Therapy Post-TKI Resistance May Improve Survival in NSCLC Patients With EGFR Mutation.
    Tian T; Yu M; Li J; Jiang M; Ma D; Tang S; Lin Z; Chen L; Gong Y; Zhu J; Zhou Q; Huang M; Lu Y
    Front Oncol; 2021; 11():739090. PubMed ID: 34888234
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-angiogenic therapy or immunotherapy? A real-world study of patients with advanced non-small cell lung cancer with EGFR/HER2 exon 20 insertion mutations.
    Li J; Xie M; Zhao R; Qiang H; Chang Q; Qian J; Lu H; Shen Y; Han Y; Su C; Chu T
    Front Oncol; 2024; 14():1357231. PubMed ID: 38567147
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of the response to platinum-based chemotherapy on the second-line immune checkpoint inhibitor monotherapy in non-small cell lung cancer with PD-L1 expression ≤49%: a multicenter retrospective study.
    Yoshimura A; Takeda T; Kataoka N; Tanimura K; Fukui M; Chihara Y; Takei S; Kawachi H; Nakanishi K; Yamanaka Y; Tamiya N; Honda R; Okura N; Yamada T; Uryu K; Murai J; Shiotsu S; Yoshioka H; Yamada T; Kurata T; Takayama K
    Front Oncol; 2024; 14():1303543. PubMed ID: 38344209
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune checkpoint inhibitors alone or in combination with chemotherapy for treatment of advanced non-small cell lung cancer after first-line platinum-based chemotherapy: A propensity score matching analysis.
    Qiu L; Gao S; Du S; Sun S; Liang Y; Sun Z; Li T; Jia G; Li K; Sun X; Jiao S; Zhao X
    Front Oncol; 2022; 12():974227. PubMed ID: 36523994
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune checkpoint inhibitors combined with angiogenic inhibitors in the treatment of locally advanced or metastatic lung adenocarcinoma patients.
    Feng Y; Tang L; Wang H; Liu Y; Yang S; Lin L; Hu X; Shi Y
    Cancer Immunol Immunother; 2023 Feb; 72(2):449-459. PubMed ID: 35934742
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of immunoradiotherapy for advanced non-small cell lung cancer: a retrospective comparative cohort study.
    Gao Y; Sun X; Hou Y; Zhang M; Tan W; Zhang Y; Wang J; Zheng Z; Li C; Qi H; Hu M; Xing L
    J Thorac Dis; 2023 Jun; 15(6):3182-3196. PubMed ID: 37426122
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative efficacy and safety of multitarget angiogenesis inhibitor combined with immune checkpoint inhibitor and nivolumab monotherapy as second-line or beyond for advanced lung adenocarcinoma in driver-negative patients: a retrospective comparative cohort study.
    Yu L; Xu J; Qiao R; Zhong H; Brueckl WM; Zhong R
    Transl Lung Cancer Res; 2023 May; 12(5):1108-1121. PubMed ID: 37323173
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Paclitaxel-bevacizumab combination in advanced non-squamous non-small-cell lung cancer (NSCLC): AVATAX, a retrospective multicentric study.
    Bilger G; Toffart AC; Darrason M; Duruisseaux M; Ulmer L; Wang P; Leprieur EG; Girard N; Massiani MA; Bore P; Descourt R; Pinsolle J; Valery S; Monnet I; Swalduz A; Tissot C; Fournel P; Baranzelli A; Cortot AB; Decroisette C
    Ther Adv Med Oncol; 2022; 14():17588359221099399. PubMed ID: 35694190
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
    Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
    Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-PD1 versus anti-PD-L1 immunotherapy in first-line therapy for advanced non-small cell lung cancer: A systematic review and meta-analysis.
    Brito ABC; Camandaroba MPG; de Lima VCC
    Thorac Cancer; 2021 Apr; 12(7):1058-1066. PubMed ID: 33586297
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic Value of the Lung Immune Prognostic Index May Differ in Patients Treated With Immune Checkpoint Inhibitor Monotherapy or Combined With Chemotherapy for Non-small Cell Lung Cancer.
    Wang W; Huang Z; Yu Z; Zhuang W; Zheng W; Cai Z; Shi L; Yu X; Lou G; Hong W; Zhang Y; Chen M; Song Z
    Front Oncol; 2020; 10():572853. PubMed ID: 33163403
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PD-1/PD-L1 Inhibitor Combined with Chemotherapy Can Improve the Survival of Non-Small Cell Lung Cancer Patients with Brain Metastases.
    Sun C; Zhou F; Li X; Zhao C; Li W; Li J; Xiong A; Yu J; Gao G; Wang Q; Wu F; Zhou C
    Onco Targets Ther; 2020; 13():12777-12786. PubMed ID: 33363383
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunotherapy beyond progression in patients with advanced non-small cell lung cancer.
    Ge X; Zhang Z; Zhang S; Yuan F; Zhang F; Yan X; Han X; Ma J; Wang L; Tao H; Li X; Zhi X; Huang Z; Hofman P; Prelaj A; Banna GL; Mutti L; Hu Y; Wang J
    Transl Lung Cancer Res; 2020 Dec; 9(6):2391-2400. PubMed ID: 33489801
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis.
    Zheng J; Shao M; Yang W; Ren J; Chen X; Yang H
    Int Immunopharmacol; 2022 Nov; 112():109244. PubMed ID: 36126410
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune checkpoint inhibitors versus second line chemotherapy for patients with lung cancer refractory to first line chemotherapy.
    Lefebvre C; Martin E; Hendriks LEL; Veillon R; Puisset F; Mezquita L; Ferrara R; Sabatier M; Filleron T; Dingemans AC; Besse B; Raherisson C; Mazières J
    Respir Med Res; 2020 Nov; 78():100788. PubMed ID: 32980653
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The efficacy of immune checkpoint inhibitors in advanced
    Hu J; Huang D; Wang Y; Li D; Yang X; Fu Y; Du N; Zhao Y; Li X; Ma J; Hu Y
    Front Immunol; 2022; 13():975246. PubMed ID: 36159795
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in NSCLC Harboring ERBB2 Mutations.
    Saalfeld FC; Wenzel C; Christopoulos P; Merkelbach-Bruse S; Reissig TM; Laßmann S; Thiel S; Stratmann JA; Marienfeld R; Berger J; Desuki A; Velthaus JL; Kauffmann-Guerrero D; Stenzinger A; Michels S; Herold T; Kramer M; Herold S; Tufman A; Loges S; Alt J; Joosten M; Schmidtke-Schrezenmeier G; Sebastian M; Stephan-Falkenau S; Waller CF; Wiesweg M; Wolf J; Thomas M; Aust DE; Wermke M;
    J Thorac Oncol; 2021 Nov; 16(11):1952-1958. PubMed ID: 34245914
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.